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A possible new pathway in natural killer
cell activation also reveals the difficulty in
determining human NK cell function in
cancer
Robert J. Canter1 and William J. Murphy2,3*
Abstract
Immunotherapy is rapidly becoming the fourth arm of cancer treatment, and breakthrough successes have been
observed in multiple malignancies. However, despite the potential for impressive anti-tumor effects, on average,
only 25% of patients respond, and barriers clearly remain. Hence, uncovering innovative ways to apply immunotherapy
and overcome immune resistance remains an unmet need in immuno-oncology. Natural killer (NK) cells are an attractive
candidate for extending the promise of immunotherapy, although success to date has been largely limited to
hematological cancers. An important study has identified novel ways in which NK cells sense and respond to tumors,
and these findings may impact clinical translation of NK cells in cancer immunotherapy. Using the activating receptor
NKp44, NK cells were shown to bind platelet-derived growth factor DD (PDGF-DD) which was secreted by tumors. Using
transgenic mice, NKp44 binding of tumor-expressed PDGF-DD was able to limit tumor growth, and expression of natural
cytotoxicity receptor-associated gene signatures (of which NKp44 is a member) was correlated to clinical outcomes. This
study highlights the potential for effector-target interactions to impact immune homeostasis in previously unrecognized
ways, while at the same time, underscoring the complexities inherent in pre-clinical/ translational experimental design
which may confound clinical application of these interesting results.
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Main text
Immunologists tend to view immune cells principally in
the context of immune-mediated signaling (i.e. cytokines
or co-stimulatory/inhibitory ligands), and as such, we tend
to overlook their general biology as cells residing in an or-
ganism responding to continuous cellular and molecular
signals, particularly in non-immune tissues. Non-immune
mediators such as growth factors, hormones, and adhesion
molecules are all utilized by immune cells. Indeed, as im-
mune cells can potentially reside anywhere, it makes sense
that these non-immune pathways also play important, pos-
sibly critical, roles in immune function. Case in point, a
recent study by Barrow et al. demonstrated that a platelet
derived growth factor (PDGF) isoform is a putative ligand
for the NK cell activating receptor, NKp44 or NCR2 [1].
NKp44 or NCR2 was initially characterized as an induced
cell surface receptor on activated human NK cells (mice
completely lack NKp44) which augmented cytolytic killing
of tumor cells in vitro [2, 3]. As a member of the human
natural cytotoxicity receptor (NCR) family, these different
receptors (NKp44, NKp30, NKp46 among others) appear
to transmit co-stimulatory signals to human NK cells and
augment their function. It was previously reported that the
ligand for NKp44 is a molecule called mixed lineage
leukemia-5 (MLL5) which is a truncated protein observed
on the surface of tumor cells [4] and later observed in
HIV-infected T cells [5]. However, using a NKp44-GFP re-
porter system, Barrow et al. screened thousands of mouse
and human proteins and demonstrated that PDGF-DD (a
homodimer of activated PDGF which has A, B, C and D
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isoforms) can augment NK cell activation via NKp44 and
induce production of cytokines such as interferon-gamma.
Furthermore, supernatants of the activated NK cells
inhibited tumor cell growth of a variety of human tumors
in vitro [1]. Unfortunately, as mice have no homolog for
NCR2 to ascertain in vivo function, generation of NCR
transgenic mice to force the expression of human NKp44
on mouse NK cells was required to assess in vivo function.
Subsequent challenge of these transgenic mice with a
mouse melanoma line transduced with human PDGF-DD
demonstrated that the NCR2-Tg mice could partially resist
tumor challenge and these anti-tumor effects could be
partially abrogated by blocking antibodies to NKp44. Fi-
nally, examining The Cancer Genome Atlas or TCGA,
PDGF-D was observed in multiple human tumors and the
presence of NCR2- activated gene expression “signatures”
correlated with superior outcome in glioblastoma but not
other cancers [1].
Several important conclusions can be drawn from this
study. First PDGF-DD can stimulate activated NK cells
by directly binding NKp44. Since NKp44 is only present
on activated NK cells, it is important to recognize that
clinical application using this approach will require prior
NK activation. However, it is of interest that the authors
focused on cytokine induction rather than CD107a de-
tection as a readout of NKp44 triggering since previous
publications have shown a dominant role of NKp44 in
augmenting cytolytic capability [2], although this may be
contingent on in vitro culture conditions and subsequent
activation status of the NK cells. Similarly, despite using
a high-throughput screen, the authors did not appear to
demonstrate binding to the previously reported ligand
for NKp44, MLL5 [4]. This may be due to variations in
cell culture conditions, differential binding of NKp44 to
cell surface molecules (such as MLL5) versus soluble
proteins (such as PDGF-DD), or the use of reporter sys-
tems not contingent on additional protein interactions
which can be a source of negative data when attempting
to link to other studies. Given the strong biologic role of
NK cells on viral resistance with profound effects on
both viral and NK cell evolution (i.e. in response to cyto-
megalovirus) [6, 7], it seems logical that virally-infected
cells also represent a source of possible targets for NK
cell activating receptors and need to be assessed particularly
in conjunction with other NK cell signaling molecules.
A critical issue in attempting to determine the possible
in vivo relevance of the human NK cell effects observed
in vitro are the striking species differences between mouse
and human NK cells, which in the current study centers
on the complete absence of NKp44 in mice. Tumor im-
munology necessitates in vivo validation and this pre-
sents a quandary given the numerous immunological
differences between mouse and man [8]. For example, the
ligands for another key NK activating receptor (NKG2D)
differ in mice and humans. In humans, NKG2D binds
the polymorphic MHC class I-like molecules MHC-I
chain-related A (MICA) and MHC-I chain-related B
(MICB), whereas in mice NKG2D binds to H-60 and
Rae1β. Creating transgenic mice bearing the human
molecules can provide a glimpse into putative in vivo
roles (outside of xenogeneic modeling using human NK
cells in immunodeficient mice). However, care must be
undertaken in extrapolating the physiologic implications
of these data as mouse NK cells have not evolved to utilize
this protein or pathway. Another caveat concerns the
transduction of mouse tumor lines with human proteins
such as PDGF-DD. The lack of competing receptors or
ligands may augment otherwise incidental effects (i.e.
human NKp44 binding to human PDGF-DD), and one
must always keep in mind that these are xenogeneic
molecules expressed in an immunologically competent
mouse. Finally, it is important to acknowledge that NCR2
expression in the TCGA database was not found to be
significant with regard to glioblastoma outcome [1], in
part due to lack of consistent NCR2 signal in the tumors
assessed. Instead, genes associated with NKp44 activation
(both cytokine and cell cycle gene clusters called “variates”)
were indirectly found to correlate with greater survival in
GBM. Although these genes are indeed associated with
NKp44 activation, they are not “specific” for NK effector
function, much less NKp44 triggering, as the majority of
these cytokine and cell-cycle activation genes are also
present on activated T cells. It would therefore be import-
ant to assess these derived signatures over a wide range of
conditions before categorizing them as true “NKp44-
specific” signatures. Thus, care must be taken before ex-
trapolating the role of NK cells in general and NKp44 in
particular with clinical outcome, particularly in the con-
text of intricate, but potentially unrepresentative, animal
models.
Yet despite these caveats, the study does open new
avenues for further exploring the role of NK cells in
cancer. It will be of particular interest to ascertain if
the role of NK cells and/or NKp44 is heightened when
oncolytic viruses are applied in GBM since NK cells
can not only target the tumor but simultaneously limit
viral efficacy. Further research is also needed to determine
why the PDGF-DD isoform is specifically upregulated in
some cancers and selected to be a target of NK cells. Fi-
nally, the study raises important questions on the in-
creasing use of targeted therapies for possible unforeseen
immune effects. PDGF inhibition has been targeted in
cancer with some success [9, 10]. However, aside from the
direct effects on the cancer, as the Barrow study high-
lights, this approach may unexpectedly result in inhibition
of NK responses. The “net” effect is likely very dependent
on the tumor type, the dependence on specific growth
factor pathways, and whether NK cells play a role in
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resistance for specific tumors. Nonetheless, the study
by Barrow et al. demonstrates that NK cells may have
evolved to recognize heightened growth factor produc-
tion as a possible “danger” signal. Whether this effect is
strong enough to be applied in cancer therapy is unre-
solved, but given the complexities of NK cells and can-
cer biology, a careful assessment of the strengths and
weaknesses of pre-clinical modeling is paramount when
interpreting the possible clinical applications of innova-
tive translational immuno-oncology studies.
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